On the 15th November 2018, Pain UK trustees attended a pharmaceutical company sponsored debate on the use of medicinal cannabis. The event included clinical, regulatory and pharmaceutical experts. Pain UK attendance was in the context of the UK government’s recent decision to reschedule cannabis products1 and interim NHS clinical guidance enabling specialist doctors to prescribe medicinal cannabis2. It is evident that there is significant debate as to the clinical …
